Superior Performance of Magnetic Nanoparticles for Entrapment and Fixation of Bovine Serum Albumin In-Vitro

BACKGROUND: In recent years, extensive studies have been performed on magnetite nanoparticles (MNPs) and their applications, which have shown the current project to be one of the major applications by laboratory results.METHODS: The nanoparticles synthesized in this project were deposited by the co-precipitation method, which structure was identified by analyzers such as SEM, FT-IR, and EDX. The aim of this project is the adsorption and fixation of biomolecule (BSA (bovine serum albumin) protein on the surface of magnetic nanoparticles.RESULTS: The adsorption results by electrophoresis and spectrophotometric analyzers showed an absorption rate above 55% ie; 55% of the protein is fixed on the MNPs nanoparticles. This absorption is due to the high level of functionality of magnetic nanoparticles for adsorption of protein. The results of the EDX analysis also show the possible electrostatic bonding between the nanoparticles and the protein, this is derived from –OH with –NH2 groups of the nanobiocompound (MNPs /protein). After bonding, the two are easily separated.CONCLUSION: In this project, the Fe3O4 nanoparticles was synthesized and identified by SEM, FT-IR, and EDX analyzers and finally reacted with the BSA protein (for the absorption of protein on MNPs) under experimental conditions at a standard temperature of 25° C. The results showed that about 55% of the protein was fixed on magnetic nanoparticles

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Study of MDR1 Gene Expression in Colorectal Cancer Using Nanobiosensor

Abstract Background: Nowadays, drug resistances are the main problems in no response of cancer patients to drug. Identification of molecular mechanisms and causative agents of drug resistance can be important to determine the treatment method in different stages of disease. In this study, for the first time, expression of multidrug resistance (MDR1) gene was studied in colorectal cancer by Carbon Nanotubes (CNTs)-based nanobiosensor method. Materials and Methods: At first, a nanobiosensor was designed based on carbon nanotubes (CNTs). After optimizing reaction condition to identify target DNA sequence, colorectal cancer patient’s cDNA samples were evaluated by nanbiosensor. Results: After immobilizing the probe on CNTs, Fluorescence immersion was quenched but by adding complementary DNA, fluorescence again was observed. In hybridization reaction of cDNA with nanobiosensor high significant levels of fluorescence emission was observed in colorectal cancer tumor samples compared normal tissue indicating high level expression of MDR1gene in tumor tissue. Conclusion: Finally, the evaluation of the expression of MDR1 gene by nanobiosensor indicated that in colorectal cancer tissue MDR1, mRNA level was higher than normal tissue. In addition, the results of this study indicated that carbon nanotubes-based nanobiosensor beside PCR-based method can be used as a very powerful tool for expression studies in human cancers at mRNA levels

Increasing cycle length and flattening power distribution in soluble boron-free small modular reactor

Population growth, industrial development as well as limited fossil fuel resources have motivated the study of other energies, especially nuclear energy. Small modular reactors have been introduced as an efficient energy source due to their greater safety, easy transport, electricity generation and water desalination, even in remote areas. Optimization in the nuclear fuel management to improve performance and save energy leads to cost-effective design with higher efficiency and better safety. In this research, core loading pattern optimization of system-integrated modular advanced reactor (SMART) has been considered using the new dragonfly algorithm. In addition to the selected algorithm, the efficiency of optimizing loading pattern also depends on the definition of the objective function. Two-objective functions including flattening the power distribution and maximizing the effective multiplication factor are considered. Simulations of the reactor fuel assemblies and reactor core were performed by DRAGON lattice calculation and PARCS core calculation codes, respectively. According to the final results, the cycle length and effective multiplication factor are increased for 185 days and 582 pcm, respectively. Also the fitness function is decreased from 0.905931 to 0.194527

Experimental study and development of mathematical model using surface response method to predict the rheological performance of CeO2-CuO/10W40 hybrid nanolubricant

In this study, the rheological behavior of CeO2-CuO/10W40 hybrid nanolubricant with several volume fractions (VFs) over the range of 0.25–1.5 vol%, temperatures over the range of 5–55 °C, and shear rates varying from 20 to 1000 rpm are experimentally assessed. The viscosity measurements at various shear rates (SRs), VFs, and temperatures demonstrated that the 10W40 engine oil and hybrid nanolubricant behave non-Newtonian. The experimental results show that the maximum viscosity reduction with increasing SR occurs at T = 45 °C and VF = 1.25 %, which its value is about 30.28 %. The experimental findings demonstrate that an increase in temperature results in reduced viscosity (between 91.84 % and 93.10 %) while the viscosity increases with increasing VF. To forecast the experimental data, two correlations (functions of three variables: temperature, VF, and SR) are presented based on experimental data using curve fitting and the response surface method (RSM). The results show that good concordance exists between experimental data and correlation results to estimate the viscosity of CeO2-CuO/10W40 hybrid nano-lubricant. Additionally, the correlation developed by the RSM is more straightforward than one derived from curve fitting. This new hybrid nano-lubricant can be used as a coolant in the automotive industry

Influence of Foreign DNA Introduction and Periplasmic Expression of Recombinant Human Interleukin-2 on Hydrogen Peroxide Quantity and Catalase Activity in Escherichia coli

Purpose: Oxidative stress is generated through imbalance between composing and decomposing of reactive oxygen species (ROS). This kind of stress was rarely discussed in connection with foreign protein production in Escherichia coli. Effect of cytoplasmic recombinant protein expression on Hydrogen peroxide concentration and catalase activity was previously reported. In comparison with cytoplasm, periplasmic space has different oxidative environment. Therefore, in present study we describe the effect of periplasmic expression of recombinant human interleukin-2 (hIL-2) on H2O2 concentration and catalase activity in Escherichia coli and their correlation with cell growth. Methods: Having constructed pET2hIL2 vector, periplasmic expression of hIL-2 was confirmed. Then, H2O2 concentration and catalase activity were determined at various ODs. Wild type and empty vector transformed cells were used as negative controls. Results: It was shown that H2O2 concentration in hIL-2 expressing cells was significantly higher than its concentration in wild type and empty vector transformed cells. Catalase activity and growth rate reduced significantly in hIL-2 expressing cells compared to empty vector transformed and wild type cells. Variation of H2O2 concentration and catalase activity is intensive in periplasmic hIL-2 expressing cells than empty vector containing cells. Correlation between H2O2 concentration elevation and catalase activity reduction with cell growth depletion are also demonstrated. Conclusion: Periplasmic expression of recombinant hIL-2 elevates the host cell’s hydrogen peroxide concentration possibly due to reduced catalase activity which has consequent suppressive effect on growth rate